IBRX

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ImmunityBio, Inc. (IBRX) [ST]

www.immunitybio.com
$7.67

6.39%

prev close

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Congressional Trades

1

All tracked trades

Members Trading

1

Unique members

Net Activity

-1

0 buys · 1 sells

Members Who Traded This Stock

1 trade events

2023-03-06

Daniel Goldman

IBRX

Sell

Amount

$1,001 - $15,000

Filed

1081d ago